ACE Inhibitor Use in Advanced CKD

Primary Recommendation

The American Journal of Kidney Diseases recommends continuing ACE inhibitor therapy in patients with eGFR 20 mL/min/1.73 m², particularly if albuminuria is present, as the renoprotective and cardiovascular benefits outweigh risks when properly monitored 1
The KDIGO guidelines explicitly state to continue ACE inhibitor or ARB therapy in CKD patients even as eGFR declines to this level 1
This recommendation applies regardless of whether the patient has diabetes, as long as moderately-to-severely increased albuminuria is present 1

Check serum creatinine, potassium, and blood pressure within 2-4 weeks of any dose initiation or adjustment, with more frequent monitoring given the low eGFR 1
Accept up to 30% rise in serum creatinine within 4 weeks - this is expected and does not require discontinuation 1
Monitor potassium closely - hyperkalemia is more likely at eGFR 20 but should be managed medically rather than stopping the ACE inhibitor 1
Assess for symptomatic hypotension - volume status becomes critical at this eGFR level 1

Consider reducing dose or stopping ACE inhibitor only in specific scenarios, including serum creatinine rises >30% within 4 weeks of initiation or dose increase, symptomatic hypotension, uncontrolled hyperkalemia despite medical treatment, or eGFR falls below 15 mL/min/1.73 m² with uremic symptoms requiring management 1

Hyperkalemia should be managed with potassium-lowering strategies rather than discontinuing the ACE inhibitor, including dietary potassium restriction, diuretic adjustment, and potassium binders if needed 1
Discontinuation should be reserved only for uncontrolled hyperkalemia despite these measures 1

Add SGLT2 inhibitor if eGFR ≥20 mL/min/1.73 m² for additional renoprotection and cardiovascular benefit, particularly in diabetic patients 1, 2
SGLT2 inhibitors are recommended at eGFR ≥20 with albuminuria ≥200 mg/g or heart failure 1
Never combine ACE inhibitor with ARB or direct renin inhibitor - this is explicitly contraindicated 1

Do not discontinue ACE inhibitor for modest creatinine rises - the initial decrease in GFR represents hemodynamic adjustment and predicts better long-term renal outcomes 1
Avoid volume depletion - at eGFR 20, patients are particularly susceptible to ACE inhibitor-induced acute kidney injury when volume depleted 1, 3
Screen for bilateral renal artery stenosis - though rare, this represents a true contraindication where ACE inhibitors can cause acute renal failure 4, 3

The renoprotective mechanism of ACE inhibitors - reducing intraglomerular pressure through efferent arteriolar vasodilation - provides long-term benefit 1
Cardiovascular protection remains critical at eGFR 20, as cardiovascular mortality exceeds risk of progression to dialysis in this population 5, 6